The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.
AstraZeneca has set itself a challenging new target to nearly double its revenues to $80bn and launch 20 new medicines by 2030.
The company earned $45.8bn in 2023 and believes it can sustain one of the best growth rates in the sector to reach its new target in six years’ time
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
